Physician profile
Daniel Benhuri
NPI 1003304189
$6,024.70
in general payments reported to CMS, 2019-2025
30 companies · $2,338 in 2025
The $2,338 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.13 · 2022: $1,475 · 2023: $669 · 2024: $1,506 · 2025: $2,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508 · Travel and Lodging: $5.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.59 |
| Travel and Lodging | $5.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $921.46 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Heartflow, INC. | $801.82 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $569.67 | 2024-2025 | Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company Ltd. | $477.44 | 2022 | |
| Novo Nordisk INC | $442.01 | 2022-2025 | Wegovy, Saxenda, Ozempic |
| Viiv Healthcare Company | $399.58 | 2022-2025 | Apretude |
| Noven Therapeutics, LLC | $372.18 | 2024-2025 | Xelstrym |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $309.50 | 2023-2024 | Lifevest |
| Supernus Pharmaceuticals, INC. | $303.64 | 2022-2025 | Qelbree, Qelbree |
| Amgen INC. | $287.40 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.56 | 2023-2024 | Jardiance |
| Corium, LLC | $132.78 | 2023-2024 | Azstarys |
| Linus Health, INC. | $95.95 | 2022 | |
| Pfizer INC. | $90.47 | 2023-2024 | |
| Baxter Healthcare | $89.42 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $83.21 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.82 | 2024-2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $50.92 | 2023 | Contrave, Nexlizet, Nexletol |
| Acella Pharmaceuticals, LLC | $33.33 | 2025 | NP Thyroid 60 |
| Phathom Pharmaceuticals, INC. | $31.23 | 2025 | Voquezna |
| Exact Sciences Corporation | $30.78 | 2025 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $29.36 | 2022 | |
| Almatica Pharma LLC | $25.42 | 2022 | |
| Shield Therapeutics INC | $25.00 | 2022 | |
| Corcept Therapeutics | $23.12 | 2025 | Korlym |
| Genentech USA, INC. | $19.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.73 | 2022 | |
| Antares Pharma, INC. | $18.16 | 2022 | |
| Tris Pharma INC | $16.61 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.73 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Benhuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.